Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Trial Profile

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs AG 881 (Primary) ; Ivosidenib (Primary)
  • Indications Glioma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms Window
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2018 According to an Agios Pharmaceuticals media release, updates from the study are being presented as part of a trials in progress poster, at the Society for Neuro-Oncology (SNO) Annual Meeting.
    • 31 Aug 2018 Biomarkers information updated
    • 01 Jun 2018 According to an Agios Pharmaceuticals media release, data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top